We assign a fundamental rating of 0 out of 10 to CHRO. CHRO was compared to 525 industry peers in the Biotechnology industry. CHRO has a bad profitability rating. Also its financial health evaluation is rather negative. CHRO has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year CHRO has reported negative net income.
CHRO had a negative operating cash flow in the past year.
CHRO had negative earnings in each of the past 5 years.
In the past 5 years CHRO always reported negative operating cash flow.

1.2 Ratios

CHRO's Return On Assets of -810.01% is on the low side compared to the rest of the industry. CHRO is outperformed by 97.33% of its industry peers.

		Industry Rank	Sector Rank
ROA	-810.01%
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CHRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CHRO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for CHRO has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -65.44, we must say that CHRO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -65.44, CHRO is not doing good in the industry: 94.48% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-65.44

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

CHRO has a Current Ratio of 0.18. This is a bad value and indicates that CHRO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CHRO (0.18) is worse than 95.73% of its industry peers.
CHRO has a Quick Ratio of 0.18. This is a bad value and indicates that CHRO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CHRO (0.18) is worse than 95.55% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.18
Quick Ratio	0.18

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for CHRO have decreased strongly by -197.60% in the last year.

EPS 1Y (TTM)-197.6%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%41.21%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CHRO will show a small growth in Earnings Per Share. The EPS will grow by 5.16% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-3.62%

EPS Next 2Y5.98%

EPS Next 3Y5.16%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CHRO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHRO. No positive earnings are expected for the next year.